Developer docs
API playgroundTry for free, no card

Search company profiles

Telomir Pharmaceuticals

Full company profile

uuid00008gt

Namestring
Telomir Pharmaceuticals
Legal namestring
Telomir Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics that modulate intracellular metal homeostasis to treat cancer and age-related disease. Its lead candidate, Telomir-1 (also referred to as Telomir-Zn), is designed to restore epigenetic regulation by redistributing zinc and iron within cells — increasing intracellular zinc while reducing redox-active ferrous iron — without relying on cytotoxic mechanisms. The lead program received FDA IND clearance in April 2026 for advanced and metastatic triple-negative breast cancer, with first-in-human Phase 1/2 trials planned for 1H 2026 at a leading U.S. academic medical center. Preclinical data also supports indications in Type 2 diabetes, Wilson's disease, prostate cancer, leukemia, pancreatic cancer, and age-related conditions including progeria and osteoarthritis, with the secondary Telomir-Ag2 program targeting drug-resistant bacterial infections.

The company is pre-revenue with no commercial products or pricing in place. Its business model is a standard clinical-stage biotech pathway: develop Telomir-Zn through Phase 1/2 trials, pursue eventual commercialization upon regulatory approval, and consider licensing, co-development partnerships, and milestone payments from larger pharmaceutical partners as supplementary revenue streams. Capital sources disclosed include a $5M non-dilutive credit line from The Starwood Trust (undrawn as of December 2024), a $1M common stock investment from the same investor at $7 per share, and up to $5M in milestone-tied funding from Bayshore Trust tied to the TELI Pharmaceuticals acquisition and FDA milestones. Operations are funded but limited: headcount is reported at 1-10, the full-time CFO has been replaced by a fractional CFO, and stock has declined 44%-72% across reporting windows. Global IP rights were consolidated through the March 2026 stock-for-stock acquisition of TELI Pharmaceuticals, and the company trades on NASDAQ under ticker TELO following a February 2024 IPO and Russell 3000 inclusion in July 2024.

Short descriptiontext

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class metal-modulating small-molecule therapeutics, with lead candidate Telomir-Zn cleared by the FDA in April 2026 for a Phase 1/2 trial in triple-negative breast cancer. Pre-revenue, pre-commercial, and publicly traded on NASDAQ as TELO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTampa, United States
HQ citystring
Tampa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic small molecules, metal homeostasis therapeutics, oncology drug development, clinical stage biotechnology, telomere biology
Industry1 code
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Drug Development and Commercialization
TypeLicensing Royalties
Description

Telomir Pharmaceuticals is a preclinical/clinical-stage biotechnology company with no commercial revenue. The company is developing Telomir-1 (Telomir-Zn) as an orally-dosed small molecule therapeutic targeting multiple age-related diseases and cancers. Revenue will be generated through eventual drug commercialization upon regulatory approval, with potential licensing, co-development partnerships, and milestone payments from larger pharmaceutical partners as additional pathways.

telomirpharma.com
2Non-Dilutive Financing
TypeProfessional Services
Description

The company has accessed non-dilutive capital through a $5 million credit line from The Starwood Trust, and raised $1 million through a common stock transaction at $7 per share. Potential milestone-based contributions of up to $4 million from Bayshore Trust are tied to FDA IND acceptance and Phase 1/2 trial initiation following the TELI Pharmaceuticals acquisition.

telomirpharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics that modulate intracellular metal homeostasis to address cancer and age-related diseases. Its lead candidate, Telomir-Zn (Telomir-1), is an orally-dosed metal-modulating epigenetic agent designed to redistribute zinc and iron intracellularly, with FDA IND clearance for triple-negative breast cancer and a Phase 1/2 trial planned for 1H 2026. A second candidate, Telomir-Ag2, is a stabilized Silver(II) antimicrobial complex targeting drug-resistant infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 40% increase in telomerase activity and telomere elongation in human normal embryonic fibroblast cells in vitro
+6 more records
Product overview1 text field

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer and age-related disease. The company's lead product is Telomir-Zn (also referred to as Telomir-1), a metal-modulating epigenetic agent advancing toward Phase 1/2 clinical trials for triple-negative breast cancer after receiving FDA IND clearance. The company has expanded its pipeline to include Telomir-Ag2, a novel antimicrobial candidate targeting drug-resistant infections. Telomir-Zn works by restoring intracellular metal homeostasis (zinc, iron, copper balance) and modulating epigenetic pathways, with preclinical efficacy demonstrated across multiple cancer models (triple-negative breast cancer, prostate cancer, leukemia, pancreatic cancer), metabolic disease (Type 2 diabetes), and rare diseases (Wilson's disease, progeria).

Product and service2 records
1Telomir-Zn (Telomir-1)
CategoryInvestigational Oncology Drug Candidate
Description

First-in-class metal-modulating epigenetic small-molecule therapeutic that restores intracellular zinc and iron homeostasis to address tumor progression, genomic instability, and treatment resistance. Lead candidate advancing toward clinical evaluation in advanced and metastatic triple-negative breast cancer (TNBC), with preclinical data also generated in prostate cancer, leukemia, pancreatic cancer, Type 2 diabetes, Wilson's disease, and age-related conditions.

2Telomir-Ag2
CategoryInvestigational Antimicrobial Drug Candidate
Description

Stabilized Silver(II) complex antimicrobial with broad-spectrum activity against drug-resistant bacteria, including methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA). Designed for potential wound care, burn centers, and surgical applications with a $30B+ addressable antimicrobial market opportunity.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1TELI Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Telomir completed acquisition of TELI Pharmaceuticals in March 2026 via stock-for-stock transaction, consolidating worldwide rights to Telomir-1 (Telomir-Zn) under a single corporate structure. The deal included $1.0 million in immediate funding at closing and up to $4.0 million additional tied to FDA IND acceptance and Phase 1/2 trial initiation milestones. Bayshore Trust, a TELI shareholder, contributed $1M at closing. Previously fragmented North American and international rights are now unified.

investing.com
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration with Smart Assays Biotechnologies for cellular studies using live-cell fluorescent probes to demonstrate Telomir-1's mechanism of action — specifically showing coordinated intracellular redistribution of zinc and iron in cultured human HaCaT cells within 30 minutes sustained over two hours. Smart Assays also conducted copper binding studies validating Telomir-1's exceptional binding affinity for copper ions.

3Recipharm
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Recipharm provided critical manufacturing and development support for Telomir-1, including GMP preparation and copper binding studies. The collaboration facilitated progress toward IND-enabling studies and manufacturing scale-up for clinical trials. Telomir also collaborated with Smart Assays on copper binding studies demonstrating Telomir-1's selective interaction with copper ions.

ir.telomirpharma.com
Strategic tierMinorTypeOthers
Description

Erez Aminov serves as Chairman and CEO of both Telomir Pharmaceuticals and MIRA Pharmaceuticals (NASDAQ: MIRA). Alan Weichselbaum serves as CFO of both companies. Ned MacPherson, Matthew Pratt Whalen, and Dr. Matthew Del Giudice serve as directors of both companies. This shared leadership and governance represents a connected corporate ecosystem between the two publicly traded biopharmaceutical companies.

5The Georgetown Group (Longevity Expert Panel)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Formed in December 2023, the Georgetown Group comprises 14 individuals from medicine, medical ethics, public relations, law, and economics who provide strategic guidance on Telomir-1's research direction. Dr. Michael Roizen (former Cleveland Clinic Chief Wellness Officer, NYT bestselling author) serves as a key member and public-facing special advisor on age reversal, presenting preclinical data at the National Press Club in April 2024.

telomirpharma.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Telomir partnered with Midwest Veterinary Services for a planned large-scale osteoarthritis study in dogs. Only the safety phase was completed (showing no adverse effects) before the company discontinued the study due to ethical concerns about inducing osteoarthritis. Telomir is now in discussions with a well-known veterinary institution to design a new study recruiting elderly dogs with naturally occurring osteoarthritis.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

India-based research organization that collaborated with Telomir on preclinical Type 2 diabetes studies in zebrafish models. The study evaluated two forms of Telomir-1 at three different doses, assessing fasting glucose, OGTT, insulin concentrations, and HOMA-IR. Results demonstrated dose-dependent efficacy in normalizing blood glucose and reducing insulin resistance to near pre-diabetic levels.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established rare-disease pharmaceutical company that commercializes treatments for genetic conditions. Directly comparable for Telomir's Wilson's disease program given BioMarin's expertise in rare/orphan drug development, commercialization, and global distribution infrastructure.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics targeting the biology of aging. Directly comparable to Telomir's longevity/age-reversal positioning, with overlapping mechanism research and target indication space (e.g., age-related metabolic decline).

TypeDirect peer
Description

Clinical-stage small-molecule biotech pursuing novel mechanisms in high-prevalence indications. Comparable in size, capital profile, and the strategy of leveraging a single platform mechanism across multiple therapeutic areas.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and metabolic diseases. Comparable in size, stage, and metabolic-disease focus (overlapping with Telomir's T2D program) — a relevant benchmark for clinical execution and capital efficiency.

TypeEmerging player
Description

Specialist pharmaceutical company focused on Wilson's disease (commercializing Cufence/trientine). Direct competitive comparable for Telomir's Wilson's disease program, representing the standard-of-care incumbent that any Telomir-Zn Wilson's program would need to displace.

TypeDirect peer
Description

Clinical-stage small-cap biotech developing novel small-molecule therapeutics for metabolic and endocrine disorders. Comparable in stage (Phase 1/2), therapeutic area overlap (T2D/metabolic disease), and business model of advancing first-in-class mechanisms toward partnering or commercialization.

TypeDirect peer
Description

Clinical-stage small-molecule biotech developing cardiometabolic and neuroscience therapies. Similar size, stage, and capital profile to Telomir; comparable challenges in advancing a single platform across multiple indications with limited resources.

TypeDirect peer
Description

Small-cap clinical-stage biopharma that recently achieved first-in-class approval (Rezdiffra for MASH). Provides a roadmap of how a small-molecule metabolic disease biotech can navigate from preclinical through approval, though with significantly more capital and headcount than Telomir.

TypeDirect peer
Description

Closest comparable given shared CEO (Erez Aminov), CFO, and multiple overlapping directors. Both are clinical-stage NASDAQ-listed biotechs with similar market caps pursuing small-molecule therapeutics. Functions as Telomir's effectively-sister company within a connected corporate ecosystem.

TypeEmerging player
Description

Aging-focused biotech developing senolytic therapeutics. Closest direct thematic comparable to Telomir's anti-aging and age-reversal positioning, though with a different mechanism (senescent cell clearance vs. metal modulation).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Telomir Pharmaceuticals

Clinical-Stage Oncology Therapeuticstelomirpharma.com

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class metal-modulating small-molecule therapeutics, with lead candidate Telomir-Zn cleared by the FDA in April 2026 for a Phase 1/2 trial in triple-negative breast cancer. Pre-revenue, pre-commercial, and publicly traded on NASDAQ as TELO.

What Telomir Pharmaceuticals does

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics that modulate intracellular metal homeostasis to treat cancer and age-related disease. Its lead candidate, Telomir-1 (also referred to as Telomir-Zn), is designed to restore epigenetic regulation by redistributing zinc and iron within cells — increasing intracellular zinc while reducing redox-active ferrous iron — without relying on cytotoxic mechanisms. The lead program received FDA IND clearance in April 2026 for advanced and metastatic triple-negative breast cancer, with first-in-human Phase 1/2 trials planned for 1H 2026 at a leading U.S. academic medical center. Preclinical data also supports indications in Type 2 diabetes, Wilson's disease, prostate cancer, leukemia, pancreatic cancer, and age-related conditions including progeria and osteoarthritis, with the secondary Telomir-Ag2 program targeting drug-resistant bacterial infections.

The company is pre-revenue with no commercial products or pricing in place. Its business model is a standard clinical-stage biotech pathway: develop Telomir-Zn through Phase 1/2 trials, pursue eventual commercialization upon regulatory approval, and consider licensing, co-development partnerships, and milestone payments from larger pharmaceutical partners as supplementary revenue streams. Capital sources disclosed include a $5M non-dilutive credit line from The Starwood Trust (undrawn as of December 2024), a $1M common stock investment from the same investor at $7 per share, and up to $5M in milestone-tied funding from Bayshore Trust tied to the TELI Pharmaceuticals acquisition and FDA milestones. Operations are funded but limited: headcount is reported at 1-10, the full-time CFO has been replaced by a fractional CFO, and stock has declined 44%-72% across reporting windows. Global IP rights were consolidated through the March 2026 stock-for-stock acquisition of TELI Pharmaceuticals, and the company trades on NASDAQ under ticker TELO following a February 2024 IPO and Russell 3000 inclusion in July 2024.

Telomir Pharmaceuticals firmographics

Firmographics
Name
Telomir Pharmaceuticals
Legal name
Telomir Pharmaceuticals, Inc.
Website
https://telomirpharma.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class metal-modulating small-molecule therapeutics, with lead candidate Telomir-Zn cleared by the FDA in April 2026 for a Phase 1/2 trial in triple-negative breast cancer. Pre-revenue, pre-commercial, and publicly traded on NASDAQ as TELO.
Ownership category
akta.pro rank

Telomir Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Epigenetic small molecules
  • Metal homeostasis therapeutics
  • Oncology drug development
  • Clinical stage biotechnology
  • Telomere biology

Where Telomir Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Tampa
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Telomir Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Telomir Pharmaceuticals is a preclinical/clinical-stage biotechnology company with no commercial revenue. The company is developing Telomir-1 (Telomir-Zn) as an orally-dosed small molecule therapeutic targeting multiple age-related diseases and cancers. Revenue will be generated through eventual drug commercialization upon regulatory approval, with potential licensing, co-development partnerships, and milestone payments from larger pharmaceutical partners as additional pathways.
  2. Non-Dilutive Financing: The company has accessed non-dilutive capital through a $5 million credit line from The Starwood Trust, and raised $1 million through a common stock transaction at $7 per share. Potential milestone-based contributions of up to $4 million from Bayshore Trust are tied to FDA IND acceptance and Phase 1/2 trial initiation following the TELI Pharmaceuticals acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Telomir Pharmaceuticals product offering

Product offering

Core offering

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics that modulate intracellular metal homeostasis to address cancer and age-related diseases. Its lead candidate, Telomir-Zn (Telomir-1), is an orally-dosed metal-modulating epigenetic agent designed to redistribute zinc and iron intracellularly, with FDA IND clearance for triple-negative breast cancer and a Phase 1/2 trial planned for 1H 2026. A second candidate, Telomir-Ag2, is a stabilized Silver(II) antimicrobial complex targeting drug-resistant infections.

Product overview

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer and age-related disease. The company's lead product is Telomir-Zn (also referred to as Telomir-1), a metal-modulating epigenetic agent advancing toward Phase 1/2 clinical trials for triple-negative breast cancer after receiving FDA IND clearance. The company has expanded its pipeline to include Telomir-Ag2, a novel antimicrobial candidate targeting drug-resistant infections. Telomir-Zn works by restoring intracellular metal homeostasis (zinc, iron, copper balance) and modulating epigenetic pathways, with preclinical efficacy demonstrated across multiple cancer models (triple-negative breast cancer, prostate cancer, leukemia, pancreatic cancer), metabolic disease (Type 2 diabetes), and rare diseases (Wilson's disease, progeria).

Differentiator

Problem solved

Functional benefit

Products and services

  • Telomir-Zn (Telomir-1) First-in-class metal-modulating epigenetic small-molecule therapeutic that restores intracellular zinc and iron homeostasis to address tumor progression, genomic instability, and treatment resistance. Lead candidate advancing toward clinical evaluation in advanced and metastatic triple-negative breast cancer (TNBC), with preclinical data also generated in prostate cancer, leukemia, pancreatic cancer, Type 2 diabetes, Wilson's disease, and age-related conditions.
  • Telomir-Ag2 Stabilized Silver(II) complex antimicrobial with broad-spectrum activity against drug-resistant bacteria, including methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA). Designed for potential wound care, burn centers, and surgical applications with a $30B+ addressable antimicrobial market opportunity.

Quantifiable outcome

  • 40% increase in telomerase activity and telomere elongation in human normal embryonic fibroblast cells in vitro
  • +6 more outcomes

Companies that use Telomir Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles3 records

Telomir Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Telomir Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • TELI PharmaceuticalscoreStrategic or Co-development PartnerTelomir completed acquisition of TELI Pharmaceuticals in March 2026 via stock-for-stock transaction, consolidating worldwide rights to Telomir-1 (Telomir-Zn) under a single corporate structure. The deal included $1.0 million in immediate funding at closing and up to $4.0 million additional tied to FDA IND acceptance and Phase 1/2 trial initiation milestones. Bayshore Trust, a TELI shareholder, contributed $1M at closing. Previously fragmented North American and international rights are now unified.
  • Smart Assays BiotechnologiescoreTechnology or IntegrationCollaboration with Smart Assays Biotechnologies for cellular studies using live-cell fluorescent probes to demonstrate Telomir-1's mechanism of action — specifically showing coordinated intracellular redistribution of zinc and iron in cultured human HaCaT cells within 30 minutes sustained over two hours. Smart Assays also conducted copper binding studies validating Telomir-1's exceptional binding affinity for copper ions.
  • RecipharmcoreStrategic or Co-development PartnerRecipharm provided critical manufacturing and development support for Telomir-1, including GMP preparation and copper binding studies. The collaboration facilitated progress toward IND-enabling studies and manufacturing scale-up for clinical trials. Telomir also collaborated with Smart Assays on copper binding studies demonstrating Telomir-1's selective interaction with copper ions.
  • MIRA PharmaceuticalsminorOthersErez Aminov serves as Chairman and CEO of both Telomir Pharmaceuticals and MIRA Pharmaceuticals (NASDAQ: MIRA). Alan Weichselbaum serves as CFO of both companies. Ned MacPherson, Matthew Pratt Whalen, and Dr. Matthew Del Giudice serve as directors of both companies. This shared leadership and governance represents a connected corporate ecosystem between the two publicly traded biopharmaceutical companies.
  • The Georgetown Group (Longevity Expert Panel)minorStrategic or Co-development PartnerFormed in December 2023, the Georgetown Group comprises 14 individuals from medicine, medical ethics, public relations, law, and economics who provide strategic guidance on Telomir-1's research direction. Dr. Michael Roizen (former Cleveland Clinic Chief Wellness Officer, NYT bestselling author) serves as a key member and public-facing special advisor on age reversal, presenting preclinical data at the National Press Club in April 2024.
  • Midwest Veterinary ServicesminorImplementation/ SI/ Consulting PartnerTelomir partnered with Midwest Veterinary Services for a planned large-scale osteoarthritis study in dogs. Only the safety phase was completed (showing no adverse effects) before the company discontinued the study due to ethical concerns about inducing osteoarthritis. Telomir is now in discussions with a well-known veterinary institution to design a new study recruiting elderly dogs with naturally occurring osteoarthritis.
  • PentagritminorImplementation/ SI/ Consulting PartnerIndia-based research organization that collaborated with Telomir on preclinical Type 2 diabetes studies in zebrafish models. The study evaluated two forms of Telomir-1 at three different doses, assessing fasting glucose, OGTT, insulin concentrations, and HOMA-IR. Results demonstrated dose-dependent efficacy in normalizing blood glucose and reducing insulin resistance to near pre-diabetic levels.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Telomir Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • BioMarin Pharmaceutical: Established rare-disease pharmaceutical company that commercializes treatments for genetic conditions. Directly comparable for Telomir's Wilson's disease program given BioMarin's expertise in rare/orphan drug development, commercialization, and global distribution infrastructure.

Emerging players

  • BioAge Labs: Clinical-stage biotech developing therapeutics targeting the biology of aging. Directly comparable to Telomir's longevity/age-reversal positioning, with overlapping mechanism research and target indication space (e.g., age-related metabolic decline).
  • Orphalan: Specialist pharmaceutical company focused on Wilson's disease (commercializing Cufence/trientine). Direct competitive comparable for Telomir's Wilson's disease program, representing the standard-of-care incumbent that any Telomir-Zn Wilson's program would need to displace.
  • Unity Biotechnology: Aging-focused biotech developing senolytic therapeutics. Closest direct thematic comparable to Telomir's anti-aging and age-reversal positioning, though with a different mechanism (senescent cell clearance vs. metal modulation).

Direct peers

  • Structure Therapeutics: Clinical-stage small-molecule biotech pursuing novel mechanisms in high-prevalence indications. Comparable in size, capital profile, and the strategy of leveraging a single platform mechanism across multiple therapeutic areas.
  • Altimmune: Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and metabolic diseases. Comparable in size, stage, and metabolic-disease focus (overlapping with Telomir's T2D program) — a relevant benchmark for clinical execution and capital efficiency.
  • Viking Therapeutics: Clinical-stage small-cap biotech developing novel small-molecule therapeutics for metabolic and endocrine disorders. Comparable in stage (Phase 1/2), therapeutic area overlap (T2D/metabolic disease), and business model of advancing first-in-class mechanisms toward partnering or commercialization.
  • Lexicon Pharmaceuticals: Clinical-stage small-molecule biotech developing cardiometabolic and neuroscience therapies. Similar size, stage, and capital profile to Telomir; comparable challenges in advancing a single platform across multiple indications with limited resources.
  • Madrigal Pharmaceuticals: Small-cap clinical-stage biopharma that recently achieved first-in-class approval (Rezdiffra for MASH). Provides a roadmap of how a small-molecule metabolic disease biotech can navigate from preclinical through approval, though with significantly more capital and headcount than Telomir.
  • MIRA Pharmaceuticals: Closest comparable given shared CEO (Erez Aminov), CFO, and multiple overlapping directors. Both are clinical-stage NASDAQ-listed biotechs with similar market caps pursuing small-molecule therapeutics. Functions as Telomir's effectively-sister company within a connected corporate ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Telomir Pharmaceuticals social profiles

Digital presence

Telomir Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Telomir Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Telomir Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Telomir Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Telomir Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telomir Pharmaceuticals

What does Telomir Pharmaceuticals do?

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics that modulate intracellular metal homeostasis to address cancer and age-related diseases. Its lead candidate, Telomir-Zn (Telomir-1), is an orally-dosed metal-modulating epigenetic agent designed to redistribute zinc and iron intracellularly, with FDA IND clearance for triple-negative breast cancer and a Phase 1/2 trial planned for 1H 2026. A second candidate, Telomir-Ag2, is a stabilized Silver(II) antimicrobial complex targeting drug-resistant infections.

Is Telomir Pharmaceuticals a public or private company?

Telomir Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Telomir Pharmaceuticals founded?

Telomir Pharmaceuticals was founded in 2021. It employs 1 to 10 people.

Where is Telomir Pharmaceuticals based?

Telomir Pharmaceuticals is headquartered in Tampa, United States, in the North America region.

How does Telomir Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Drug Development and Commercialization is the primary driver. The others are non-Dilutive Financing.

Who are Telomir Pharmaceuticals's main competitors?

BioMarin Pharmaceutical is listed as a broad incumbent. Emerging players are BioAge Labs, Orphalan and Unity Biotechnology. Direct peers are Structure Therapeutics, Altimmune, Viking Therapeutics, Lexicon Pharmaceuticals, Madrigal Pharmaceuticals and MIRA Pharmaceuticals.

Does Telomir Pharmaceuticals have an API?

No public API is recorded for Telomir Pharmaceuticals.

What industry is Telomir Pharmaceuticals in?

Telomir Pharmaceuticals's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerTelomir Pharmaceuticals Inc Selects Linical to Advance Fda-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast CancerTelomir Pharmaceuticals selected Linical to support its FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer. The company signed a Master Services Agreement and Work Order, targeting clinical initiation in the first quarter of 2027. The trial will evaluate safety, tolerability, and preliminary antitumor activity of the oral epigenetic therapy.TradingViewTelomir Pharmaceuticals Selects Linical for Phase 1/2 TNBC TrialTelomir Pharmaceuticals selected Linical to support its FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer. The companies executed a Master Services Agreement and clinical trial Work Order, with clinical initiation targeted for the first quarter of 2027. The study will evaluate the drug's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity as a monotherapy.FinancialContent Business PageInvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Raises Approximately $5.6 Million in PIPE FinancingTelomir Pharmaceuticals raised approximately $5.6 million in PIPE financing, issuing 4,843,300 shares at $1.16 per share, a 5% discount to the 10-day VWAP. The company will use the proceeds primarily for clinical development of Telomir-Zn, including its Phase 1/2 trial in advanced or metastatic triple-negative breast cancer, and for working capital.Longevity.TechnologyTelomir-Zn improves vision, aging markers in zebrafishTelomir Pharmaceuticals announced that its compound Telomir-Zn improved vision and restored retinal layers in zebrafish with age-related retinal degeneration. The treatment also lowered oxidative stress and raised telomere content toward healthy levels. The company's clinical priority remains oncology, with a Phase 1/2 trial in triple-negative breast cancer.AInvestTelomir (TELO): The Cash Runs Out About When the Data Should BeginTelomir Pharmaceuticals has about $5.2 million in cash and burned $1.7 million in Q2 2026, covering roughly three quarters into early 2027. Its FDA-cleared Telomir-Zn trial starts in Q1 2027, but funding is conditional on milestones, and each equity raise has been at a lower price, diluting the share count.FinancialContent Business PageBioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Telomir-Zn Improvements in Visual Function and Retinal Structure in AMD ModelTelomir Pharmaceuticals published preclinical data showing Telomir-Zn improved visual function, restored retinal structure, and reduced oxidative stress in an age-related macular degeneration model. The treatment also restored DNA methylation patterns and increased telomeric DNA content. The company's clinical development remains focused on oncology, with Telomir-Zn advancing in a Phase 1/2 trial for triple-negative breast cancer.Longevity.TechnologyTelomir-Zn inhibits bone cancer cell growth in early studyTelomir announced a collaboration with Ohio State University, reporting preclinical in vitro findings that Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines. The study showed dose-dependent anti-tumor activity at similar low concentrations across three cell lines. The company plans to assess next steps for an in vivo efficacy study in canine osteosarcoma.AInvestTelomir (TELO): A Real Ohio State Result, but a Stock That Still Rests on an Unstarted TrialTelomir Pharmaceuticals reported in-vitro data from Ohio State showing its candidate Telomir-Zn inhibited growth in three osteosarcoma cell lines. The stock fell about 2.5% on the news, but the company's lead program is a TNBC trial that has not started, and its cash runway is under a year.Markets DailyTelomir Pharmaceuticals (TELO) Expected to Post Quarterly Earnings on WednesdayTelomir Pharmaceuticals is expected to report quarterly earnings after market close on September 2nd, with analysts projecting a loss of $0.07 per share. The stock opened at $1.12, and the company's consensus rating is Hold, with Weiss Ratings reiterating a sell rating.Longevity.TechnologyTelomir-Zn halts prostate and breast cancer growth in early studyTelomir Pharmaceuticals published preclinical data demonstrating that Telomir-Zn inhibits tumor growth in prostate and triple-negative breast cancer models. The study reports that Telomir-Zn modulates iron and copper to inhibit histone demethylases, leading to tumor suppression and reactivation of tumor-suppressor genes.